trending Market Intelligence /marketintelligence/en/news-insights/trending/x2_QOKc8qAymGGvot8IlQg2 content esgSubNav
In This List

China approves launch of Roche's Perjeta for breast cancer

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


China approves launch of Roche's Perjeta for breast cancer

China's National Medical Products Administration approved the importation of Roche Holding AG's Perjeta as a treatment for HER2-positive breast cancer, in combination with Herceptin and chemotherapy.

Perjeta, also known as pertuzumab, works by preventing the human epidermal growth factor receptor 2, or HER2, from pairing with other HER receptors on the surface of cancer cells. Binding of Perjeta to HER2 may also signal the immune system to destroy cancer cells.

Herceptin, also marketed by Roche, was included in China's national drug reimbursement list in 2017.

SNL Image